Table 4.
Glucose-related events from the first injection through open-label extension phasea
| Recently diagnosed (n = 216) | Chronically ill (n = 429) | |
|---|---|---|
| Subjects with a glucose-related adverse event, n (%) | 6 (2.8) | 22 (5.1) |
| Specific glucose-related event, n (%) | ||
| Blood glucose increased | 4 (1.9) | 17 (4.0) |
| Hyperglycemia | 1 (0.5) | 3 (0.7) |
| Diabetes mellitus | 1 (0.5) | 2 (0.5) |
| Increased insulin requirement | 2 (0.9) | 1 (0.2) |
| Diabetic complication | 0 (0) | 1 (0.2) |
| Glucose tolerance impaired | 0 (0) | 1 (0.2) |
| Type 2 diabetes mellitus | 0 (0) | 1 (0.2) |
Notes:
a
A subject experiencing more than one adverse event within a system organ class/preferred term is counted once within that system organ class/preferred term for incidence.